Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

How Does Obesity Cause Large Bowel (Colon and Rectum) Cancer?

How Does Obesity Cause Large Bowel (Colon and Rectum) Cancer?

Many studies have demonstrated for some time that there is a biological relationship between obesity and large bowel (colorectal) cancer. A study whose results were recently announced showed that a drug approved by the FDA for irritable bowel syndrome could prevent colorectal cancer development. The findings were published in the journal Cancer Research.

Obese people have been shown to have a 50% higher risk of developing colorectal cancer than lean people. In mouse studies at Thomas Jefferson University in Philadelphia investigating the relationship between obesity and colorectal cancer, obesity associated with excessive fat, carbohydrate consumption, or both was found to be related to loss of the hormone guanylin and its activity. Guanylin is a protein hormone produced in the secretory surface cells of the intestine called goblet cells.

The surface of the intestines is highly active and constantly renews itself. A receptor, guanylyl cyclase C (GUCY2C), contributes to this regeneration. Guanylin is the hormone that stimulates this receptor.

The findings showed that a high-calorie diet switches off guanylin expression in the intestine, leading to inactivation of the tumor suppression pathway.

Low Guanylin Expression Sets the Stage for Tumors

One characteristic of colorectal cancer is inactivation of the guanylin gene. This occurs in both humans and animals. Guanylin gene expression is 80% lower in obese people than in lean people.

The guanylin hormone receptor has been found to function as a tumor-suppressing growth control. Without this hormone, the receptor remains silent from the early stages of cancer. This causes the epithelium to lose its function and creates conditions for cancer development.

To verify their findings, the researchers created mice with transgenes that prevented the guanylin gene from being switched off. In this way, cancer development was prevented by switching on the tumor suppressor even when the mice consumed excessive calories.

The research showed that the hormone and its receptor were more silent in obese mice than in lean mice. This study suggested that colorectal cancer could be prevented by giving obese people hormone replacement treatment, just as diabetes is treated with insulin.

The researchers conducting the study believe they have finally found a major clue to the origin of colorectal cancer in obese people, and perhaps in other people as well. They also believe that colorectal cancer develops through this silent mechanism and that this development occurs more often in obese people.

Linaclotide Could Replace the Missing Hormone

Additional findings showed that a drug structurally related to the missing hormone, linaclotide (Linzess) could be used to prevent colorectal cancer in obese people.

Linaclotide was approved by the United States Food and Drug Administration (FDA) in 2012 to treat the constipation form of irritable bowel syndrome and chronic constipation of unknown cause, known as chronic idiopathic constipation.

The researchers also showed that calorie restriction reversed excessive calorie consumption and restored guanylin expression even in obese mice, and recommended lifestyle changes.

Further research is needed to identify this molecular mechanism that stops hormone production. Meanwhile, studies on the dose and adverse effects of linaclotide are continuing.

Sources

Jieru E. Lin, Francheska Colon-Gonzalez, Erik Blomain.
Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin–GUCY2C Paracrine Signaling Axis.
Cancer Res. 2016 Jan 15;76(2):339-46. doi: 10.1158/0008-5472.CAN-15-1467-T.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

How Does Obesity Cause Large Bowel (Colon and Rectum) Cancer?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy